KindlyMD, Inc. (NASDAQ:NAKA) Receives $19.33 Consensus Target Price from Brokerages

KindlyMD, Inc. (NASDAQ:NAKA) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.3333.

NAKA has been the topic of a number of analyst reports. TD Cowen lifted their price target on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Finally, B. Riley Financial increased their price target on shares of KindlyMD from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd.

Insiders Place Their Bets

In other KindlyMD news, CEO David F. Bailey bought 4,852 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $6.27 per share, with a total value of $30,422.04. Following the completion of the purchase, the chief executive officer owned 3,185,246 shares of the company’s stock, valued at approximately $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have bought a total of 41,904 shares of company stock valued at $235,231 in the last 90 days. 24.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD in the fourth quarter worth about $167,000. Virtu Financial LLC purchased a new stake in KindlyMD during the fourth quarter valued at $151,000. Invesco Ltd. bought a new position in shares of KindlyMD in the 4th quarter worth approximately $211,000. NewEdge Advisors LLC bought a new position in KindlyMD in the fourth quarter worth approximately $316,000. Finally, Saba Capital Management L.P. bought a new position in KindlyMD in the 4th quarter worth $1,399,000.

KindlyMD Stock Performance

NASDAQ NAKA opened at $8.19 on Monday. KindlyMD has a 52-week low of $3.33 and a 52-week high of $143.60. The company has a fifty day moving average of $5.61 and a 200-day moving average of $6.83. The company has a market capitalization of $146.60 million, a P/E ratio of -0.23 and a beta of 15.99.

KindlyMD (NASDAQ:NAKA) last released its earnings results on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The firm had revenue of $35.87 million during the quarter. As a group, analysts forecast that KindlyMD will post -12.87 EPS for the current fiscal year.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.